-
★
COVID-19: NEUE DATEN ZU MOLNUPIRAVIR (LAGEVRIO)
(Hinzugefügt: 10.11.2022 um 13:43 Uhr)
https://www.arznei-telegramm.de/html/2022_10/2210413_01.html
-
★
Antivirale Therapie in der Frühphase einer SARS-CoV-2-Infektion bei Patienten mit Risikofaktoren für einen schweren Verlauf von COVID-19 (bei asymptomatischen Patienten oder Patienten mit milder COVID-19)
(Hinzugefügt: 25.10.2022 um 13:55 Uhr)
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/COVRIIN_Dok/Antivirale_Therapie_Fruehphase.pdf?__blob=publicationFile
-
★
COVID-19-Therapieempfehlungen: Interaktive Orientierungshilfe für Ärztinnen und Ärzte
(Hinzugefügt: 30.05.2022 um 14:11 Uhr)
https://www.dgiin.de/covriin/index.html#/sub/asymptomatic
-
★
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
(Hinzugefügt: 28.11.2021 um 15:17 Uhr)
https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/
-
★
EU-Arzneimittelbehörde lässt erstes Coronamedikament in Tablettenform zu
(Hinzugefügt: 19.11.2021 um 20:55 Uhr)
https://www.aerzteblatt.de/nachrichten/129273/EU-Arzneimittelbehoerde-laesst-erstes-Coronamedikament-in-Tablettenform-zu
-
★
First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA
(Hinzugefügt: 04.11.2021 um 18:38 Uhr)
https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra
-
★
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
(Hinzugefügt: 11.03.2021 um 08:36 Uhr)
https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/
-
Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients
(Hinzugefügt: 10.04.2023 um 13:58 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad181/7091553
-
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
(Hinzugefügt: 30.12.2022 um 15:15 Uhr)
https://www.bmj.com/content/379/bmj-2022-071932
-
Antiviral treatments lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients
(Hinzugefügt: 30.12.2022 um 15:10 Uhr)
https://www.medrxiv.org/content/10.1101/2022.12.21.22283811v1
-
Molnupiravir doesn't cut Omicron hospitalization, death but can speed recovery
(Hinzugefügt: 30.12.2022 um 15:09 Uhr)
https://www.cidrap.umn.edu/covid-19/molnupiravir-doesnt-cut-omicron-hospitalization-death-can-speed-recovery
-
Schnellere Genesung von Covid-19 dank Molnupiravir
(Hinzugefügt: 30.12.2022 um 14:58 Uhr)
https://www.pharmazeutische-zeitung.de/schnellere-genesung-von-covid-19-dank-molnupiravir-137533/
-
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
(Hinzugefügt: 30.12.2022 um 14:43 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext
-
Therapiekritik COVID-19: NEUE DATEN ZU MOLNUPIRAVIR (LAGEVRIO)
(Hinzugefügt: 28.12.2022 um 14:39 Uhr)
https://www.arznei-telegramm.de/html/2022_10/2210413_01.html
-
Approval for molnupiravir (MOV) use should be revoked worldwide. Not only has it proven ineffective, it seems... to be creating sequences
(Hinzugefügt: 29.11.2022 um 16:17 Uhr)
https://twitter.com/longdeserttrain/status/1597353291868155906?s=48&t=DNrrHsdbHff6rpVhgdHH9Q
-
Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial
(Hinzugefügt: 19.11.2022 um 19:59 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4237902
-
Lagevrio/Paxlovid: Was gilt beim Privatrezept?
(Hinzugefügt: 25.10.2022 um 13:35 Uhr)
https://www.pta-in-love.de/lagevrio-paxlovid-was-gilt-beim-privatrezept/
-
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
(Hinzugefügt: 25.10.2022 um 13:24 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00644-2/fulltext
-
NIRMATRELVIR PLUS RITONAVIR (PAXLOVID) UND MOLNUPIRAVIR (LAGEVRIO)
(Hinzugefügt: 24.06.2022 um 09:51 Uhr)
https://www.arznei-telegramm.de/html/2022_06/2206045_01.html
-
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19FREE
(Hinzugefügt: 24.06.2022 um 09:36 Uhr)
https://www.acpjournals.org/doi/10.7326/M22-0729
-
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study
(Hinzugefügt: 27.05.2022 um 07:40 Uhr)
https://www.medrxiv.org/content/10.1101/2022.05.19.22275291v1
-
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform
(Hinzugefügt: 25.05.2022 um 15:32 Uhr)
https://www.medrxiv.org/content/10.1101/2022.05.22.22275417v1
-
Oral Antiviral Medications for COVID-19
(Hinzugefügt: 13.05.2022 um 07:38 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2791780
-
Informationen zu Lagevrio®
(Hinzugefügt: 10.05.2022 um 08:19 Uhr)
https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/covid-19-arzneimittel.html
-
Molnupiravir’s authorisation was premature
(Hinzugefügt: 22.03.2022 um 11:44 Uhr)
https://www.bmj.com/content/376/bmj.o443
-
Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations
(Hinzugefügt: 18.03.2022 um 09:34 Uhr)
https://www.thelancet.com/action/showPdf?pii=S2666-5247%2822%2900061-1
-
Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
(Hinzugefügt: 15.03.2022 um 16:15 Uhr)
https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-ajtmh.21-1339/article-10.4269-ajtmh.21-1339.xml
-
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
(Hinzugefügt: 17.02.2022 um 07:15 Uhr)
https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-demonstrated-activity-against-omicron-variant-in-in-vitro-studies/
-
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
(Hinzugefügt: 17.02.2022 um 06:57 Uhr)
https://www.nature.com/articles/s41422-022-00618-w
-
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
(Hinzugefügt: 17.02.2022 um 06:49 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2119407
-
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
(Hinzugefügt: 17.02.2022 um 06:35 Uhr)
https://www.science.org/doi/10.1126/scitranslmed.abl7430
-
EMA might deny Merck's molnupiravir conditional marketing authorization — report
(Hinzugefügt: 17.02.2022 um 05:39 Uhr)
https://endpts.com/ema-might-deny-mercks-molnupiravir-conditional-marketing-authorization-report/
-
ANTIVIRALE MITTEL FÜR DIE FRÜHTHERAPIE BEI COVID-19?
(Hinzugefügt: 31.01.2022 um 16:09 Uhr)
https://www.arznei-telegramm.de/html/2022_01/2201001_01.html
-
COVID-19 Therapeutics for Nonhospitalized Patients
(Hinzugefügt: 24.01.2022 um 19:56 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2788254
-
Molnupiravir to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19
(Hinzugefügt: 24.01.2022 um 16:28 Uhr)
https://www.recoverytrial.net/news/molnupiravir-to-be-investigated-by-the-recovery-trial-as-a-potential-treatment-for-patients-hospitalised-with-covid-19
-
Phase-3-Studie bestätigt Wirksamkeit von Molnupiravir bei nicht-hospitalisierten COVID-19-Erkrankten
(Hinzugefügt: 12.01.2022 um 11:07 Uhr)
https://dgn.org/neuronews/journal_club/phase-3-studie-bestaetigt-wirksamkeit-von-molnupiravir-bei-nicht-hospitalisierten-covid-19-erkrankten/
-
A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
(Hinzugefügt: 11.01.2022 um 10:13 Uhr)
https://www.science.org/doi/10.1126/scitranslmed.abl7430
-
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
(Hinzugefügt: 10.01.2022 um 13:09 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2116044
-
SEIT 3. JANUAR MÖGLICH Bestellung von Lagevrio – was ist zu beachten?
(Hinzugefügt: 10.01.2022 um 12:52 Uhr)
https://www.deutsche-apotheker-zeitung.de/news/artikel/2022/01/04/bestellung-von-lagevrio-was-ist-zu-beachten
-
Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates
(Hinzugefügt: 10.01.2022 um 12:47 Uhr)
https://www.biorxiv.org/content/10.1101/2022.01.03.474773v1
-
Molnupiravir: long-term safety questions linger as approvals approach
(Hinzugefügt: 30.12.2021 um 11:38 Uhr)
https://www.pharmaceutical-technology.com/features/molnupiravir-safety-questions-approvals-approach/
-
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
(Hinzugefügt: 30.12.2021 um 11:33 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.27.474275v1
-
A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
(Hinzugefügt: 29.12.2021 um 15:53 Uhr)
https://www.science.org/doi/10.1126/scitranslmed.abl7430
-
Bundesregierung will neu entwickelte Corona-Medikamente beschaffen
(Hinzugefügt: 25.12.2021 um 15:33 Uhr)
https://www.spiegel.de/politik/deutschland/corona-bundesregierung-bemueht-sich-um-beschaffung-neu-entwickelter-medikamente-a-5dcbd40d-3f0e-4545-8adc-da0f7b21b35a
-
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
(Hinzugefügt: 18.12.2021 um 14:12 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2116044
-
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
(Hinzugefügt: 17.12.2021 um 09:39 Uhr)
https://www.merck.com/news/merck-and-ridgeback-announce-publication-of-phase-3-study-of-molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-in-the-new-england-journal-of-medicine/
-
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
(Hinzugefügt: 04.12.2021 um 18:52 Uhr)
https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/
-
Bund schließt Liefervertrag für Coronamedikament Lagevrio
(Hinzugefügt: 03.12.2021 um 18:19 Uhr)
https://www.aerzteblatt.de/nachrichten/129679/Bund-schliesst-Liefervertrag-fuer-Coronamedikament-Lagevrio
-
COVID-19: FDA-Berater uneins über Nutzen und Risiken von Molnupiravir
(Hinzugefügt: 01.12.2021 um 17:57 Uhr)
https://www.aerzteblatt.de/nachrichten/129610/COVID-19-FDA-Berater-uneins-ueber-Nutzen-und-Risiken-von-Molnupiravir
-
Studienergebnis zu Molnupiravir Corona-Pille wirkt weniger als erhofft
(Hinzugefügt: 28.11.2021 um 15:13 Uhr)
https://www.n-tv.de/panorama/Corona-Pille-wirkt-weniger-als-erhofft-article22960268.html
-
Antiviral activity of molnupiravir precursor NHC against Variants of Concern (VOCs) and its therapeutic window in a human lung cell model
(Hinzugefügt: 25.11.2021 um 12:24 Uhr)
https://www.biorxiv.org/content/10.1101/2021.11.23.469695v1
-
EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19
(Hinzugefügt: 20.11.2021 um 11:07 Uhr)
https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19
-
Schutz vor schweren Verläufen EMA unterstützt Einsatz von Corona-Pille für Notfälle
(Hinzugefügt: 20.11.2021 um 11:06 Uhr)
https://www.n-tv.de/panorama/EMA-unterstuetzt-Einsatz-von-Corona-Pille-fuer-Notfaelle-article22943162.html
-
Großbritannien lässt Molnupiravir zur Behandlung von COVID-19 zu
(Hinzugefügt: 06.11.2021 um 09:33 Uhr)
https://www.aerzteblatt.de/nachrichten/128810/Grossbritannien-laesst-Molnupiravir-zur-Behandlung-von-COVID-19-zu
-
First pill to treat Covid gets approval in UK
(Hinzugefügt: 04.11.2021 um 18:41 Uhr)
https://www.bbc.com/news/health-59163899
-
Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
(Hinzugefügt: 04.11.2021 um 18:39 Uhr)
https://pubs.acs.org/doi/10.1021/acscentsci.1c00608
-
Estimated cost-based generic prices for molnupiravir for the treatment of COVID-19 infection
(Hinzugefügt: 04.11.2021 um 18:38 Uhr)
https://scholar.harvard.edu/melissabarber/publications/estimated-cost-based-generic-prices-molnupiravir-treatment-covid-19
-
COVID-19: Europäische Arzneimittelagentur prüft Zulassung von Molnupiravir
(Hinzugefügt: 26.10.2021 um 09:04 Uhr)
https://www.aerzteblatt.de/nachrichten/128456/COVID-19-Europaeische-Arzneimittelagentur-prueft-Zulassung-von-Molnupiravir
-
Molnupiravir Mutations
(Hinzugefügt: 18.10.2021 um 10:25 Uhr)
https://www.science.org/content/blog-post/molnupiravir-mutations
-
FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment
(Hinzugefügt: 18.10.2021 um 09:45 Uhr)
https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meeting-discuss-merck-and-ridgebacks-eua-application-covid-19-oral
-
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
(Hinzugefügt: 18.10.2021 um 09:41 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136050/
-
How antiviral pill molnupiravir shot ahead in the COVID drug hunt
(Hinzugefügt: 18.10.2021 um 09:40 Uhr)
https://www.nature.com/articles/d41586-021-02783-1
-
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
(Hinzugefügt: 12.10.2021 um 10:36 Uhr)
https://www.merck.com/news/merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-u-s-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-c/
-
Tablette gegen Corona: Wie das Medikament Molnupiravir wirkt
(Hinzugefügt: 07.10.2021 um 06:46 Uhr)
https://www.br.de/nachrichten/wissen/wie-gut-ist-das-neue-corona-medikament-molnupiravir,Sl378vi
-
COVID-19: Oraler Wirkstoff Molnupiravir halbiert Hospitalisierungs- und Sterberate bei früher ambulanter Therapie
(Hinzugefügt: 03.10.2021 um 08:16 Uhr)
https://www.aerzteblatt.de/nachrichten/127820/COVID-19-Oraler-Wirkstoff-Molnupiravir-halbiert-Hospitalisierungs-und-Sterberate-bei-frueher-ambulanter-Therapie
-
Molnupiravir: Thor's Hammer Delivers
(Hinzugefügt: 02.10.2021 um 18:20 Uhr)
https://www.science.org/content/blog-post/molnupiravir-thor-s-hammer-delivers
-
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
(Hinzugefügt: 02.10.2021 um 18:20 Uhr)
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
-
Molnupiravir: coding for catastrophe
(Hinzugefügt: 02.10.2021 um 18:09 Uhr)
https://www.nature.com/articles/s41594-021-00657-8
-
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
(Hinzugefügt: 27.09.2021 um 09:59 Uhr)
https://www.sciencedirect.com/science/article/pii/S2352396421003881
-
"Molnupiravir hat Potenzial" Hoffnung auf neues Corona-Medikament
(Hinzugefügt: 24.08.2021 um 16:26 Uhr)
https://www.n-tv.de/wissen/Hoffnung-auf-neues-Corona-Medikament-article22751801.html
-
Wie das potenzielle Coronamedikament Molnupiravir wirkt
(Hinzugefügt: 24.08.2021 um 16:21 Uhr)
https://www.aerzteblatt.de/nachrichten/126486/Wie-das-potenzielle-Coronamedikament-Molnupiravir-wirkt
-
Molnupiravir, an Oral Antiviral Treatment for COVID-19
(Hinzugefügt: 20.06.2021 um 17:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1
-
USA planen milliardenschwere Bestellung von Coronamedikament
(Hinzugefügt: 11.06.2021 um 05:38 Uhr)
https://www.aerzteblatt.de/nachrichten/124567/USA-planen-milliardenschwere-Bestellung-von-Coronamedikament
-
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
(Hinzugefügt: 13.05.2021 um 17:27 Uhr)
https://www.jbc.org/article/S0021-9258(21)00563-9/fulltext
-
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
(Hinzugefügt: 06.05.2021 um 09:27 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.03.21256309v1
-
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
(Hinzugefügt: 16.04.2021 um 12:26 Uhr)
https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/
-
Merck’s Little Brown Pill Could Transform the Fight Against Covid
(Hinzugefügt: 26.03.2021 um 20:49 Uhr)
https://www.bloomberg.com/news/features/2021-03-25/merck-mrk-molnupiravir-pill-could-change-the-fight-against-covid
-
Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data
(Hinzugefügt: 18.03.2021 um 21:56 Uhr)
https://www.fiercebiotech.com/biotech/merck-has-better-luck-second-covid-drug-attempt-as-it-sees-a-positive-early-molnupiravir
-
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
(Hinzugefügt: 14.12.2020 um 07:22 Uhr)
https://www.nature.com/articles/s41564-020-00835-2
-
Molnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model
(Hinzugefügt: 11.12.2020 um 22:44 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.10.419242v1
-
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
(Hinzugefügt: 11.12.2020 um 07:45 Uhr)
https://clinicaltrials.gov/ct2/show/NCT04405739
-
Molnupiravir Wikipedia
(Hinzugefügt: 10.12.2020 um 09:46 Uhr)
https://en.wikipedia.org/wiki/Molnupiravir